Title:
STABLE ANTI-IFNAR1 FORMULATION
Document Type and Number:
Japanese Patent JP2022066345
Kind Code:
A
Abstract:
To provide a stable, low viscosity antibody formulation comprising a high concentration of anti-INFAR1 antibody.SOLUTION: In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interferon α1 (INFAR1); about 20 mM to about 80 mM of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation.SELECTED DRAWING: None
Inventors:
ROBERTO DEPAZ
NATALIE DEJESUS
JARED BEE
NATALIE DEJESUS
JARED BEE
Application Number:
JP2022031581A
Publication Date:
April 28, 2022
Filing Date:
March 02, 2022
Export Citation:
Assignee:
ASTRAZENECA AB
International Classes:
A61K39/395; A61K9/08; A61K47/10; A61K47/18; A61K47/20; A61K47/26; A61K47/36; A61P1/04; A61P3/10; A61P13/12; A61P17/00; A61P17/06; A61P19/02; A61P21/00; A61P29/00; A61P37/02; A61P43/00
Attorney, Agent or Firm:
Michiko Matsutani
Norifumi Tomita
Fumio Inai
Manami Sasakura
Norifumi Tomita
Fumio Inai
Manami Sasakura